Treatment options for recurrent/metastatic sinonasal cancer (RMSNC) patients are limited. We present two cases with RMSNC treated with a combination of immune checkpoint blockade and hypo-fractionated stereotactic radiotherapy (HSRT). , Case 1 presented with RMSNC three months after the primary treatment. The patient progressed under first-line chemotherapy and pembrolizumab was offered. The disease progressed after the sixth cycle. We performed reirradiation with HSRT to the primary site. Case 2 presented with local recurrence eight years after the primary treatment for maxillary sinus cancer. He refused surgery and chemotherapy and was offered nivolumab treatment. After two doses, we performed reirradiation with HSRT., Case 1 showed regre...
International audienceThe survival of patients with head and neck squamous cancer with locoregional ...
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SR...
The emergence of novel systemic therapies has spurred a dramatic paradigm shift in lung cancer treat...
Background: Undifferentiated pleomorphic sarcoma (UPS) of the maxillary sinus is an extremely rare m...
Background: Undifferentiated pleomorphic sarcoma (UPS) of the maxillary sinus is an extremely rare m...
Simple Summary Despite recent developments in immune checkpoint inhibitors, the treatment of locoreg...
Abstract Background Treatment of recurrent nasopharyngeal carcinoma is a challenging clinical proble...
Head and neck squamous cell carcinoma (HNSCC) presents as locally advanced disease in a majority of ...
Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of ca...
Despite the progress of surgery, radiotherapy, and neoadjuvant chemotherapy, the prognosis for advan...
Item does not contain fulltextPURPOSE: Due to the rarity and the variety of histological types of si...
IMMUNE CHECKPOINT THERAPY AND STEREOTACTIC RADIOSURGERY FOR MELANOMA BRAIN METASTASES. Jack M. Qian,...
A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors, which lim...
To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell car...
Background The rate of loco-regional recurrences for locally advanced head and neck squamous cell...
International audienceThe survival of patients with head and neck squamous cancer with locoregional ...
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SR...
The emergence of novel systemic therapies has spurred a dramatic paradigm shift in lung cancer treat...
Background: Undifferentiated pleomorphic sarcoma (UPS) of the maxillary sinus is an extremely rare m...
Background: Undifferentiated pleomorphic sarcoma (UPS) of the maxillary sinus is an extremely rare m...
Simple Summary Despite recent developments in immune checkpoint inhibitors, the treatment of locoreg...
Abstract Background Treatment of recurrent nasopharyngeal carcinoma is a challenging clinical proble...
Head and neck squamous cell carcinoma (HNSCC) presents as locally advanced disease in a majority of ...
Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of ca...
Despite the progress of surgery, radiotherapy, and neoadjuvant chemotherapy, the prognosis for advan...
Item does not contain fulltextPURPOSE: Due to the rarity and the variety of histological types of si...
IMMUNE CHECKPOINT THERAPY AND STEREOTACTIC RADIOSURGERY FOR MELANOMA BRAIN METASTASES. Jack M. Qian,...
A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors, which lim...
To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell car...
Background The rate of loco-regional recurrences for locally advanced head and neck squamous cell...
International audienceThe survival of patients with head and neck squamous cancer with locoregional ...
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SR...
The emergence of novel systemic therapies has spurred a dramatic paradigm shift in lung cancer treat...